In 1897, Dr Victor Eisenmenger described a 32-year-old man with a history of cyanosis and
progressive exertional breathlessness since childhood. The patient developed heart failure …

The first description of Eisenmenger syndrome was provided over a 100 years ago, and the
concept of Eisenmenger reaction, with progressive pulmonary vascular disease and …

Aims Eisenmenger syndrome (ES) is associated with considerable morbidity and mortality.
Therapeutic strategies have changed during the 2000s in conjunction with an emphasis on …

The objective of this study was to determine the long-term survival pattern and variables
affecting long-term survival and complications occurring during follow-up of patients with …

Although there have been recent advances in the understanding of the pathophysiology and
management of the Eisenmenger syndrome, there is still no cure for this disease. The …

Abstract Background The management of Eisenmenger syndrome (ES) has dramatically
changed since the advent of disease-targeted therapy (DTT). However, guidelines for ES …

Eisenmenger syndrome (ES) represents the most severe phenotype of pulmonary arterial
hypertension (PAH) associated with congenital heart disease (CHD) and occurs in patients …

Objectives To investigate survival in patients with Eisenmenger syndrome based on a
systematic review of the literature and reanalysis of data. We specifically tested the …

Objective—Pulmonary arterial hypertension (PAH), associated with congenital heart disease
(CHD), usually results from a systemic-to-pulmonary shunt. Eisenmenger syndrome (ES) is …

The patient had undergone closure of a large ventricular septal defect (VSD) via medial
sternotomy at the age of 8 yrs elsewhere. At the time, the patient had a left-to-right shunt with …